Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $35.71 Consensus PT from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have earned an average rating of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $35.71.

Several analysts have commented on DAWN shares. Needham & Company LLC raised their target price on shares of Day One Biopharmaceuticals from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and increased their price objective for the stock from $11.00 to $24.00 in a report on Thursday, August 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, August 1st.

Insiders Place Their Bets

In related news, insider Samuel C. Blackman sold 2,232 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $31,248.00. Following the transaction, the insider now directly owns 1,127,535 shares of the company’s stock, valued at $15,785,490. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total transaction of $426,600.00. Following the sale, the insider now directly owns 1,097,535 shares of the company’s stock, valued at approximately $15,606,947.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Samuel C. Blackman sold 2,232 shares of Day One Biopharmaceuticals stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $31,248.00. Following the transaction, the insider now owns 1,127,535 shares in the company, valued at approximately $15,785,490. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,748 shares of company stock worth $1,009,272 over the last ninety days. Corporate insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of hedge funds have recently bought and sold shares of DAWN. Deerfield Management Company L.P. Series C raised its holdings in shares of Day One Biopharmaceuticals by 65.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock valued at $40,281,000 after purchasing an additional 1,157,825 shares during the period. Estuary Capital Management LP boosted its holdings in Day One Biopharmaceuticals by 82.5% in the first quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock worth $26,616,000 after acquiring an additional 728,240 shares in the last quarter. Ally Bridge Group NY LLC acquired a new stake in Day One Biopharmaceuticals in the second quarter valued at approximately $7,387,000. Braidwell LP increased its holdings in shares of Day One Biopharmaceuticals by 13.5% during the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock valued at $61,547,000 after acquiring an additional 500,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Day One Biopharmaceuticals by 28.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock worth $30,935,000 after purchasing an additional 472,654 shares during the period. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Up 2.6 %

DAWN opened at $13.88 on Wednesday. The stock has a market cap of $1.22 billion, a P/E ratio of -7.12 and a beta of -1.51. Day One Biopharmaceuticals has a 12 month low of $9.67 and a 12 month high of $18.07. The company has a fifty day simple moving average of $13.88 and a 200 day simple moving average of $14.43.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.70. The business had revenue of $8.19 million during the quarter, compared to the consensus estimate of $0.90 million. On average, equities research analysts expect that Day One Biopharmaceuticals will post -1.68 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.